logo
ScreenersREIT EarningsREIT SectorsIndustries
Logo

Lantern Pharma Inc.

LTRN

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers wā€¦ read more

Healthcare

Biotechnology

6 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$2.34

Price

+2.18%

$0.05

$2.29

Previous Close

$2.34

Open

Premium

52w Discount
Market Cap

$29.856m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$15.912m

+7.0%

1y CAGR

-1.8%

3y CAGR

-4.4%

5y CAGR
EPS

-$1.45

+7.6%

1y CAGR

-43715.8%

3y CAGR

-32789.9%

5y CAGR
Book Value

$3.446m

$7.223m

Assets

$3.777m

Liabilities

$59.080k

Debt
Debt to Assets

0.8%

-

Debt to EBITDA
Free Cash Flow

-$15.075m

+3.9%

1y CAGR

-2.7%

3y CAGR

-5.1%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.